论文部分内容阅读
膀胱移行上皮细胞癌(TCC)在泌尿生殖系肿瘤中最为多见,近年发病有所上升。TCC大多数为表浅性膀胱癌(pTa-1,G1-3),约占70～75%,另25～30%为浸润性TCC。表浅性膀胱癌(STC)的生物学行为变化较大,70%STC电切后1年内复发,复发者10～15%恶化(浸润兼/或转移),电切后予以膀胱内灌注化疗可减慢或阻止其复发和恶化;小部份STC易恶化,对辅助治疗不敏感;极少部份STC不易恶化和复发,电切后可不必辅助治疗。基于以上情况,依据某些预后参数预测STC为易恶化或为易复发性肿瘤,对采取何种治疗如TURBT
Bladder transitional cell carcinoma (TCC) is most common in genitourinary tumors, and the incidence has been increasing in recent years. TCC is mostly superficial bladder cancer (pTa-1, G1-3), accounting for about 70 to 75%, the other 25 to 30% of invasive TCC. The biological behavior of superficial bladder cancer (STC) changed greatly. 70% of STC patients relapsed within 1 year after the resection, and 10-15% of them had worsen (infiltration and / or metastasis) after transurethral resection. Slow or stop its recurrence and deterioration; a small part of the deterioration of STC, adjuvant therapy is not sensitive; very few STC is not easy to worsen and relapse, after cutting without adjuvant therapy. Based on the above, based on some prognostic parameters to predict STC is easy to malignant or recurrent tumors, what kind of treatment to take such as TURBT